https://www.selleckchem.com/products/b-ap15.html Virologist Dr María Guadalupe Guzmán is recognized as a global leader in dengue research and heads the Pedro Kourí Tropical Medicine Institute's work as a WHO/PAHO Collaborating Center for the Study of Dengue and Its Vector. The Institute (IPK) was founded in 1937 and is now Cuba's national reference center for the diagnosis, treatment, control and prevention of communicable diseases. Dr Guzmán is also president of the Cuban Society of Microbiology and Parasitology and directs IPK's Scientifi c Council, which is responsible for setting the Institute's research priorities. A recent h-index analysis found that Dr Guzmán is among the most widelypublished and cited Cuban researchers.On August 13, 2020, Cuba's national regulatory agency, the Center for Quality Control of Medicines, Equipment and Medical Devices (CECMED), authorized clinical trials for SOBERANA 01-Cuba's fi rst vaccine candidate and the fi rst from Latin America and the Caribbean. On August 24, parallel Phase I/II double blind, randomized, controlled clinical trials were launched at clinical sites in Havana to evaluate the vaccine's safety and immunogenicity. Analysis of results and development of different formulations are currently under way and Phase III clinical trials are planned for early 2021. At the time of writing, a second vaccine candidate, SOBERANA 02, was in late-stage development and preparing to begin separate trials this fall.We are all fatigued, frazzled. Many of us have lost too many and too much, and still more will suffer long-term physical and mental effects. A strange geography has cropped into our lexicon states, provinces and entire countries mapped by their rates of COVID-19, telling us how dangerous it is to go outside, go to work or school. It is also the geography of health care, leadership and policies that aim to protect people fi rst-or not-the willingness to embrace the simply brilliant and brilliantly simple lessons of publi